NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

NeuroSense announce the completion of enrollment in PARADIGM, a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS).

The study enrolled 69 participants living with ALS in Israel, Italy, and Canada.

PrimeC has Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Share:

Join Our Newsletter

Skip to content